YAP1 and cancer: Previous studies have highlighted key modification sites, such as Thr241 and Ser109, that enhance YAP's pro‐tumorigenic capacity in liver and other cancers.[31, 32] O‐GlcNAcylation, a modification driven by the hexosamine biosynthetic pathway (HBP), uses UDP‐GlcNAc synthesized from extracellular glucose.